Literature DB >> 29353201

miR-204 inhibits angiogenesis and promotes sensitivity to cetuximab in head and neck squamous cell carcinoma cells by blocking JAK2-STAT3 signaling.

Qingwei Wu1, Yingying Zhao1, Peihua Wang2.   

Abstract

This study aims to investigate the roles of miR-204 in tumor angiogenesis of head and neck squamous cell carcinoma (HNSCC). Here, we found that miR-204 level was reduced in HNSCC tissues relative to that in normal adjacent tissues. Overexpression of miR-204 promoted tumor angiogenesis in HNSCC cells. Mechanistically, JAK2 was identified as a direct target of miR-204, and miR-204 overexpression blocked JAK2/STAT3 pathway. Moreover, overexpression of JAK2 attenuated the inhibition of miR-204 on tumor angiogenesis of HNSCC. Furthermore, overexpression of miR-204 enhanced sensitivity of cetuximab in HNSCC cells, this effect was attenuated by JAK2 overexpression too. Importantly, JAK2 expression was negatively correlated with miR-204 level in HNSCC tissues. Therefore, miR-204 acts as a tumor suppressor by blocking JAK2/STAT3 pathway in HNSCC cells.
Copyright © 2018 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  miR-204 JAK2/STAT3 tumor angiogenesis head and neck squamous cell carcinoma cetuximab

Mesh:

Substances:

Year:  2018        PMID: 29353201     DOI: 10.1016/j.biopha.2018.01.055

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  11 in total

1.  Long noncoding RNA neuroblastoma-associated transcript 1 gene inhibits malignant cellular phenotypes of bladder cancer through miR-21/SOCS6 axis.

Authors:  Zhongyuan Liu; Dalong Xie; Hui Zhang
Journal:  Cell Death Dis       Date:  2018-10-11       Impact factor: 8.469

Review 2.  Enhanced Inhibition of Tumorigenesis Using Combinations of miRNA-Targeted Therapeutics.

Authors:  Svetlana Miroshnichenko; Olga Patutina
Journal:  Front Pharmacol       Date:  2019-05-16       Impact factor: 5.988

3.  MicroRNA-204-5p is a tumor suppressor and potential therapeutic target in head and neck squamous cell carcinoma.

Authors:  Zehang Zhuang; Pei Yu; Nan Xie; Yue Wu; Haichao Liu; Ming Zhang; Yifan Tao; Weiwang Wang; Hanqi Yin; Bin Zou; Jinsong Hou; Xiqiang Liu; Jiong Li; Hongzhang Huang; Cheng Wang
Journal:  Theranostics       Date:  2020-01-01       Impact factor: 11.556

Review 4.  Precision Medicine Approaches to Overcome Resistance to Therapy in Head and Neck Cancers.

Authors:  Sandra Ortiz-Cuaran; Jebrane Bouaoud; Andy Karabajakian; Jérôme Fayette; Pierre Saintigny
Journal:  Front Oncol       Date:  2021-02-25       Impact factor: 6.244

Review 5.  Angioregulatory microRNAs in breast cancer: Molecular mechanistic basis and implications for therapeutic strategies.

Authors:  Mohammad Hasan Soheilifar; Nastaran Masoudi-Khoram; Soheil Madadi; Sima Nobari; Hamid Maadi; Hoda Keshmiri Neghab; Razieh Amini; Mahboubeh Pishnamazi
Journal:  J Adv Res       Date:  2021-06-26       Impact factor: 12.822

6.  Down-regulation of long non-coding RNA HOTAIR inhibits invasion and migration of oesophageal cancer cells via up-regulation of microRNA-204.

Authors:  Ai-Hua Wang; Peng Tan; Yuan Zhuang; Xiu-Tian Zhang; Zong-Bu Yu; Lu-Ning Li
Journal:  J Cell Mol Med       Date:  2019-08-07       Impact factor: 5.310

Review 7.  Targeting Autophagy for Overcoming Resistance to Anti-EGFR Treatments.

Authors:  Yoojung Kwon; Misun Kim; Hyun Suk Jung; Youngmi Kim; Dooil Jeoung
Journal:  Cancers (Basel)       Date:  2019-09-16       Impact factor: 6.639

8.  Preclinical Evaluation of the Association of the Cyclin-Dependent Kinase 4/6 Inhibitor, Ribociclib, and Cetuximab in Squamous Cell Carcinoma of the Head and Neck.

Authors:  Gabrielle van Caloen; Sandra Schmitz; Cédric van Marcke; Xavier Caignet; Antonella Mendola; Sébastien Pyr Dit Ruys; Pierre P Roger; Didier Vertommen; Jean-Pascal Machiels
Journal:  Cancers (Basel)       Date:  2021-03-12       Impact factor: 6.639

Review 9.  MicroRNAs in head and neck squamous cell carcinoma: a possible challenge as biomarkers, determinants for the choice of therapy and targets for personalized molecular therapies.

Authors:  Mahrou Vahabi; Giovanni Blandino; Silvia Di Agostino
Journal:  Transl Cancer Res       Date:  2021-06       Impact factor: 1.241

10.  Upregulation of microRNA-204 improves insulin resistance of polycystic ovarian syndrome via inhibition of HMGB1 and the inactivation of the TLR4/NF-κB pathway.

Authors:  Bin Jiang; Min Xue; Dabao Xu; Yujia Song; Shujuan Zhu
Journal:  Cell Cycle       Date:  2020-02-23       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.